» Articles » PMID: 35139373

Dissecting Fc Signatures of Protection in Neonates Following Maternal Influenza Vaccination in a Placebo-controlled Trial

Overview
Journal Cell Rep
Publisher Cell Press
Date 2022 Feb 9
PMID 35139373
Authors
Affiliations
Soon will be listed here.
Abstract

Influenza is an important cause of illness and morbidity for infants. Seasonal influenza vaccination during pregnancy aims to provide protection to mothers, but it can also provide immunity to infants. The precise influence of maternal vaccination on immunity in infants and how vaccine-elicited antibodies provide protection in some but not all infants is incompletely understood. We comprehensively profiled the transfer of functional antibodies and defined humoral factors contributing to immunity against influenza in a clinical trial of maternal influenza vaccination. Influenza-specific antibody subclass levels, Fc ɣ receptor (FCGR) binding levels, and antibody-dependent innate immune functions were all profiled in the mothers during pregnancy and at birth, as well as in cord blood. Vaccination increased influenza-specific antibody levels, antibody binding to FCGR, and specific antibody-dependent innate immune functions in both maternal and cord blood, with FCGR binding most enhanced via vaccination. Influenza-specific FCGR binding levels were lower in cord blood of infants who subsequently developed influenza infection. Collectively these data suggest that in addition to increased antibody amounts, the selective transfer of FCGR-binding antibodies contributes to the protective immune response in infants against influenza.

Citing Articles

Anti-TNF therapy impairs both short- and long-term IgG responses after repeated vaccination.

Buhre J, Pongracz T, Geisen U, Schubert M, Wang W, Nouta J Allergy. 2024; 80(2):423-439.

PMID: 39049686 PMC: 11804311. DOI: 10.1111/all.16241.


Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice.

Muralidharan A, Gravel C, Harris G, Hashem A, Zhang W, Safronetz D Hum Vaccin Immunother. 2022; 18(5):2083428.

PMID: 35724343 PMC: 9621047. DOI: 10.1080/21645515.2022.2083428.

References
1.
Cousins S . Reaching Nepal's mobile population at risk of HIV. Lancet HIV. 2018; 5(11):e613-e614. DOI: 10.1016/S2352-3018(18)30298-4. View

2.
Stapleton N, Andersen J, Stemerding A, Bjarnarson S, Verheul R, Gerritsen J . Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun. 2011; 2:599. PMC: 3247843. DOI: 10.1038/ncomms1608. View

3.
Gross P, Hermogenes A, Sacks H, Lau J, Levandowski R . The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995; 123(7):518-27. DOI: 10.7326/0003-4819-123-7-199510010-00008. View

4.
Henkle E, Steinhoff M, Omer S, Roy E, Arifeen S, Raqib R . Incidence of influenza virus infection in early infancy: a prospective study in South Asia. Pediatr Infect Dis J. 2010; 30(2):170-3. DOI: 10.1097/INF.0b013e3181f63c39. View

5.
Brown E, Licht A, Dugast A, Choi I, Bailey-Kellogg C, Alter G . High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J Immunol Methods. 2012; 386(1-2):117-23. PMC: 3475184. DOI: 10.1016/j.jim.2012.09.007. View